Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Figures

• 

  Figure 1.. Enrollment flowchart.

• 

  Figure 2.. Comparison of geometric mean titers (GMTs) (A), proportion of children achieving seroconversion (B), and seroprotection (C) between groups, before vaccine (day 0) and postvaccine administration (days 28, 56, 90, 180, 360, and 720). (A) The GMTs were calculated as the antilog of the mean of the log transformation of titers for all the children within a group. (B) Seroconversion was defined as a 50% plaque reduction neutralization titer (PRNT50) of >10 U/mL if the baseline titer was <10 U/mL or as a 4-fold increase if the baseline titer was >10 U/mL. (C) Seroprotection was defined as the proportion of children with a PRNT50 >10 U/mL. A significant difference was observed between JENVAC and SA 14-14-2 groups (P < .05) at the respective day represented with 95% confidence intervals.

• 

  Figure 3.. Comparison of geometric mean titers among treatment groups stratified by age. Geometric mean titers are based on 50% plaque reduction neutralization titers represented with 95% confidence intervals. Age stratified groups were classified as (A) ≥1 to ≤5 years, (B) 5> to ≤10 years, and (C) >10 to ≤15 years.

• 

  Figure 4.. Comparison of geometric mean titers among boosted and interchanged treatment groups. Geometric mean titers are based on 50% plaque reduction neutralization titers represented with 95% confidence intervals.